Operational Milestone #1
A Phase I/II trial is being conducted to evaluate safety and efficacy of a heart-derived cell therapy in patients with cardiac dysfunction secondary to Duchenne muscular dystrophy. The grantee manufactured sufficient quantities of the cell product to supply the trial during this reporting period. The trial completed enrollment and dosing during this reporting period. All patients are undergoing follow up per protocol.